Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC
April 1st 2021The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy.
Camidanlumab Tesirine Under Investigation in Relapsed/Refractory Hodgkin Lymphoma
March 16th 2021The safety and efficacy of the antibody-drug conjugate camidanlumab tesirine is under investigation in patients with relapsed/refractory Hodgkin lymphoma as part of a phase 2 clinical trial, which recently completed accrual.
Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer
March 3rd 2021Darolutamide plus ADT will be evaluated versus ADT alone in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE study as part Bayer and Orion Corporation’s growing clinical development program for the oral AR inhibitor in prostate cancer.